Skip to content

   Pharma Publications

Neuropsychopharmacology
  • For those with schizophrenia, does cannabidiol make cannabis use safer?
    Published on 2025-08-26
    11 months ago
  • Leveraging high-resolution brain imaging and (epi)genomic approaches to improve women’s mental health
    Published on 2025-08-26
    11 months ago
  • Methylone promotes neurite outgrowth and has long-lasting effects on fear extinction learning
    Published on 2025-08-23
    11 months ago
  • Blood and neuronal extracellular vesicle mitochondrial disruptions in schizophrenia
    Published on 2025-08-23
    11 months ago
  • The role of the prelimbic cortex to nucleus accumbens core projection in the reinstatement of cocaine-seeking after cocaine-alcohol polysubstance use
    Published on 2025-08-21
    11 months ago
  • Hearing and early life adversity: effects of developmental stress on sensory processing
    Published on 2025-08-21
    11 months ago
  • Knockdown of USP22 alleviates LPS-induced microglial inflammation and mouse depressive-like behaviors via KAT2A
    Published on 2025-08-20
    11 months ago
« Previous 1 … 43 44 45 46 47 … 143 Next »
Journal of Psychopharmacology
  • Navigating the challenge of patient selection and scales to measure outcomes in ketamine trials for treatment-resistant depression
    Published on 2024-09-12
    2 years ago
  • Safety, tolerability and pharmacokinetics of the phosphodiesterase 2 inhibitor BI 474121: An overview of phase I randomized trials in healthy volunteers
    Published on 2024-09-12
    2 years ago
  • Blackcurrant (Ribes nigrum L.) improves cholinergic signaling and protects against chronic Scopolamine-induced memory impairment in mice
    Published on 2024-09-12
    2 years ago
  • Long-read sequencing of CYP2D6 may improve psychotropic prescribing and treatment outcomes: A systematic review and meta-analysis
    Published on 2024-09-12
    2 years ago
  • Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms, function and cognition in early phase schizophrenia in a double-blind, 2 × 2 factorial design, randomised controlled comparison with simvastatin
    Published on 2024-09-05
    2 years ago
  • Is lack of goal-conflict-specific rhythmicity a biomarker for treatment resistance in generalised anxiety but not social anxiety or major depression?
    Published on 2024-09-02
    2 years ago
  • High-dose Vitamin-B6 reduces sensory over-responsivity
    Published on 2024-08-24
    2 years ago
« Previous 1 … 43 44 45 46 47 … 150 Next »
European Neuropsychopharmacology
  • Deciphering the impact of metabolic anomalies in relation to severe mental illness
    Published on 2024-07-17
    2 years ago
  • Mixed features in mood episodes: Mismatch between intensity and valence in emotional responses
    Published on 2024-07-17
    2 years ago
  • Ketamine and new targets for treatment-resistant depression: A role for transforming growth factor-β1?
    Published on 2024-07-17
    2 years ago
  • Minor physical anomalies in schizophrenia and first-degree relatives in comparison to healthy controls: A systematic review and meta-analysis
    Published on 2024-06-29
    2 years ago
  • Shared vulnerability and sex-dependent polygenic burden in psychotic disorders
    Published on 2024-06-28
    2 years ago
  • Gray matter volumetric correlates of the polygenic risk of depression: A study of the Human Connectome Project data
    Published on 2024-06-27
    2 years ago
  • Open science in biomedicine: Overcoming barriers in omics studies
    Published on 2024-06-27
    2 years ago
« Previous 1 … 43 44 45 46 47 … 168 Next »

   Pharma Pub